

## DAFTAR PUSTAKA

- Albakova, Z., Armeev, G. A., Kanevskiy, L. M., Kovalenko, E. I., & Sapozhnikov, A. M. (2020). HSP70 Multi-Functionality in Cancer. *Cells*, 9(3), 1–26. <https://doi.org/10.3390/cells9030587>
- Annunziata, C. M., Kleinberg, L., Davidson, B., Berner, A., Gius, D., Tchabo, N., Steinberg, S. M., & Kohn, E. C. (2007). BAG-4/SODD and associated antiapoptotic proteins are linked to aggressiveness of epithelial ovarian cancer. *Clinical Cancer Research*, 13(22), 6585–6592. <https://doi.org/10.1158/1078-0432.CCR-07-0327>
- Bacalbasa, N., Dima, S., Balescu, I., David, L., Brasoveanu, V., & Popescu, I. (2015). *Results of Primary Cytoreductive Surgery in Advanced-stage Epithelial Ovarian Cancer : A Single-center Experience*. 4104, 4099–4104.
- Berek, J. S., Kehoe, S. T., Kumar, L., & Friedlander, M. (2018). Cancer of the ovary, fallopian tube, and peritoneum. *International Journal of Gynecology and Obstetrics*, 143, 59–78. <https://doi.org/10.1002/ijgo.12614>
- Bhatla, N., & Denny, L. (2018). *FIGO Cancer Report 2018*. 143, 2–3. <https://doi.org/10.1002/ijgo.12608>
- Bray, F., Ferlay, J., & Soerjomataram, I. (2018). *Global Cancer Statistics 2018 : GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries*. 394–424. <https://doi.org/10.3322/caac.21492>
- Chang, L. C., Huang, C. F., Lai, M. S., Shen, L. J., Wu, F. L. L., & Cheng, W. F. (2018). Prognostic factors in epithelial ovarian cancer: A population-based study. *PLoS ONE*, 13(3), 1–11. <https://doi.org/10.1371/journal.pone.0194993>
- Chang, S., Bristow, R. E., & Ryu, H. (2012). *Impact of Complete Cytoreduction*

*Leaving No Gross Residual Disease Associated with Radical Cytoreductive Surgical Procedures on Survival in Advanced Ovarian Cancer.* 4059–4067.  
<https://doi.org/10.1245/s10434-012-2446-8>

Chatterjee, S., Chen, L., Tergas, A. I., Burke, W. M., Hou, J. Y., Hu, J. C., Ananth, C. V., Neugut, A. I., Hershman, D. L., & Wright, J. D. (2016). Utilization and outcomes of chemotherapy in women with intermediate-risk, early-stage ovarian cancer. *Obstetrics and Gynecology*, 127(6), 992–1002.  
<https://doi.org/10.1097/AOG.0000000000001404>

Chen, Yun; Liu, Yingqiu and Dorn, G. 2011. (2011). 基因的改变 NIH Public Access.  
*Bone*, 23(1), 1–7. <https://doi.org/10.1309/AJCPTK87EMMIKPFS.S100A1>

Choudhury, K. R., Yagle, K. J., Swanson, P. E., Krohn, K. A., & Rajendran, J. G. (2010). A robust automated measure of average antibody staining in immunohistochemistry images. *Journal of Histochemistry and Cytochemistry*, 58(2), 95–107. <https://doi.org/10.1369/jhc.2009.953554>

Cohen, M., Dromard, M., & Petignat, P. (2010). Heat shock proteins in ovarian cancer: A potential target for therapy. *Gynecologic Oncology*, 119(1), 164–166.  
<https://doi.org/10.1016/j.ygyno.2010.05.027>

Colombo, N., Sessa, C., Bois, A. Du, Ledermann, J., McCluggage, W. G., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., Baert, T., Belaroussi, I., Dashora, A., Olbrecht, S., Planchamp, F., & Querleu, D. (2019). ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. *International Journal of Gynecological Cancer*, 29(4), 728–760.  
<https://doi.org/10.1136/ijgc-2019-000308>

Colombo, Nicoletta, Gorp, T. Van, Parma, G., Amant, F., Gatta, G., Sessa, C., & Vergote, I. (2006). *Ovarian cancer*. 60, 159–179.

<https://doi.org/10.1016/j.critrevonc.2006.03.004>

Corrado, G., Salutari, V., Palluzzi, E., Distefano, M. G., Scambia, G., & Ferrandina, G. (2017). ovarian cancer ce pt t. *Expert Review of Anticancer Therapy*, 0(0).  
<https://doi.org/10.1080/14737140.2017.1398088>

Cuylan, Z. F., Meydanli, M. M., Sari, M. E., Akbayir, O., Celik, H., Dede, M., Sahin, H., Gungorduk, K., Kuscu, E., Ozgul, N., Gungor, T., & Ayhan, A. (2018). *Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin / paclitaxel chemotherapy*. 1–10. <https://doi.org/10.1111/jog.13663>

Ditto, A., Leone Roberti Maggiore, U., Bogani, G., Martinelli, F., Chiappa, V., Evangelista, M. T., Liberale, V., Ferrero, S., & Raspagliesi, F. (2019). Predictive factors of recurrence in patients with early-stage epithelial ovarian cancer. *International Journal of Gynecology and Obstetrics*, 145(1), 28–33.  
<https://doi.org/10.1002/ijgo.12769>

Duska, L. R., & Kohn, E. C. (2017). The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications. *Annals of Oncology*, 28(Supplement 8), viii8–viii12.  
<https://doi.org/10.1093/annonc/mdx445>

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., Rubinstein, L., Shankar, L., Dodd, L., Kaplan, R., Lacombe, D., & Verweij, J. (2009). New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). *European Journal of Cancer*, 45(2), 228–247.  
<https://doi.org/10.1016/j.ejca.2008.10.026>

ELPEK, G. O., KARAVELI, S., SIMSEK, T., KELES, N., & AKSOY, N. H. (2003). Expression of heat-shock proteins hsp27, hsp70 and hsp90 in malignant epithelial

- tumour of the ovaries. Correlation with clinicopathologic factors and survival. *Apmis*, 111(4), 523–530. <https://doi.org/10.1034/j.1600-0463.2003.1110411.x>
- Ferlay, J. (2018). *Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods*. 1–13. <https://doi.org/10.1002/ijc.31937>
- Giampaolino, P., Foreste, V., Corte, L. Della, Di Filippo, C., Iorio, G., & Bifulco, G. (2020). Role of biomarkers for early detection of ovarian cancer recurrence. *Gland Surgery*, 9(4), 1102–1111. <https://doi.org/10.21037/gs-20-544>
- Gupta, N., Jagadish, N., Surolia, A., & Suri, A. (2017). Heat shock protein 70-2 (HSP70-2) a novel cancer testis antigen that promotes growth of ovarian cancer. *American Journal of Cancer Research*, 7(6), 1252–1269.
- Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. *Cell*, 144(5), 646–674. <https://doi.org/10.1016/j.cell.2011.02.013>
- Hew, K. E., Bakhru, A., Harrison, E., Turan, M. O., MacDonald, R., Im, D. D., & Rosenshein, N. B. (2013). The Effect of Obesity on the Time to Recurrence in Ovarian Cancer: A Retrospective Study. *Clinical Ovarian and Other Gynecologic Cancer*, 6(1–2), 31–35. <https://doi.org/10.1016/j.cogc.2014.02.002>
- Hoter, A., & Naim, H. Y. (2019). Heat shock proteins and ovarian cancer: Important roles and therapeutic opportunities. *Cancers*, 11(9), 1–29. <https://doi.org/10.3390/cancers11091389>
- Ilankoon, I. M. P. S., Samarasinghe, K., & Elgán, C. (2021). Menopause is a natural stage of aging: a qualitative study. *BMC Women's Health*, 21(1), 1–9. <https://doi.org/10.1186/s12905-020-01164-6>
- Investigator, P. (2019). *Management of Epithelial Ovarian Cancer at A Tertiary Centre In South Africa : A Retrospective Evaluation of Early Recurrence and Contributory Factors*. December.

- John, G., Rustin, S., Vergote, I., Eisenhauer, E., Pujade-lauraine, E., Quinn, M., Thigpen, T., Bois, A., & Kristensen, G. (2011). *Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIIG)*. *21*(2), 419–423. <https://doi.org/10.1097/IGC.0b013e3182070f17>
- Kang, H.-J., Moon, H.-S., & Chung, H.-W. (2014). The expression of FAS-associated factor 1 and heat shock protein 70 in ovarian cancer. *Obstetrics & Gynecology Science*, *57*(4), 281. <https://doi.org/10.5468/ogs.2014.57.4.281>
- Kim, S. J., Rosen, B., Fan, I., Ivanova, A., Mclaughlin, J. R., Risch, H., Narod, S. A., & Kotsopoulos, J. (2017). *Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer. November 2016*, 964–971. <https://doi.org/10.1038/bjc.2017.35>
- Koshiyama, M., Matsumura, N., & Konishi, I. (2017). Subtypes of Ovarian Cancer and Ovarian Cancer Screening. *Diagnostics*, *7*(1), 12. <https://doi.org/10.3390/diagnostics7010012>
- Krell, D., Said Battistino, F., Benaffif, S., Ganegoda, L., Hall, M., & Rustin, G. J. S. (2017). Audit of CA125 follow-up after first-line therapy for ovarian cancer. *International Journal of Gynecological Cancer*, *27*(6), 1118–1122. <https://doi.org/10.1097/IGC.0000000000000956>
- Kumar, S. J., Stokes, J., Singh, U. P., Scissum Gunn, K., Acharya, A., Manne, U., & Mishra, M. (2016). Targeting Hsp70: A possible therapy for cancer. *Cancer Letters*, *374*(1), 156–166. <https://doi.org/10.1016/j.canlet.2016.01.056>
- Li, X.-F., Hua, T., Li, Y., Tian, Y.-J., Huo, Y., & Kang, S. (2021). The HSP70 gene predicts prognosis and response to chemotherapy in epithelial ovarian cancer. *Annals of Translational Medicine*, *9*(9), 806–806. <https://doi.org/10.21037/atm-21-2087>

- Liu, X. X., Ye, H., Wang, P., Li, L. X., Zhang, Y., & Zhang, J. Y. (2017). Proteomic-based identification of HSP70 as a tumor-associated antigen in ovarian cancer. *Oncology Reports*, *37*(5), 2771–2778. <https://doi.org/10.3892/or.2017.5525>
- Marcus, C. S., Maxwell, G. L., Darcy, K. M., Hamilton, C. A., & Mcguire, W. P. (2014). *Current Approaches and Challenges in Managing and Monitoring Treatment Response in Ovarian Cancer*. 5. <https://doi.org/10.7150/jca.7810>
- Momenimovahed, Z., Tiznobaik, A., Taheri, S., & Salehiniya, H. (2019). Ovarian cancer in the world: Epidemiology and risk factors. *International Journal of Women's Health*, *11*, 287–299. <https://doi.org/10.2147/IJWH.S197604>
- Nagle, C. M., Dixon, S. C., Jensen, A., Kjaer, S. K., Modugno, F., DeFazio, A., Fereday, S., Hung, J., Johnatty, S. E., Fasching, P. A., Beckmann, M. W., Lambrechts, D., Vergote, I., Van Nieuwenhuysen, E., Lambrechts, S., Risch, H. A., Rossing, M. A., Doherty, J. A., Wicklund, K. G., ... Webb, P. M. (2015). Obesity and survival among women with ovarian cancer: Results from the Ovarian Cancer Association Consortium. *British Journal of Cancer*, *113*(5), 817–826. <https://doi.org/10.1038/bjc.2015.245>
- Onal, Y., Kostek, O., Hacıoglu, M., Erdogan, B., Kodaz, H., Bekmez, E., Hacibekiroglu, I., Uzunoglu, S., & Cicin, I. (2017). Assessment of Prognostic Factors in Epithelial Ovarian Cancer. *Eurasian Journal of Medicine and Oncology*, *1*(2), 61–68. <https://doi.org/10.14744/ejmo.2017.43531>
- Park, S. H., Baek, K. H., Shin, I., & Shin, I. (2018). Subcellular Hsp70 Inhibitors Promote Cancer Cell Death via Different Mechanisms. *Cell Chemical Biology*, *25*(10), 1242-1254.e8. <https://doi.org/10.1016/j.chembiol.2018.06.010>
- Pearce, C. L., Templeman, C., Rossing, M. A., Lee, A., Near, A. M., Webb, P. M., Nagle, C. M., Doherty, J. A., Cushing-Haugen, K. L., Wicklund, K. G., Chang-Claude, J., Hein, R., Lurie, G., Wilkens, L. R., Carney, M. E., Goodman, M. T.,

- Moysich, K., Kjaer, S. K., Hogdall, E., ... Berchuck, A. (2012). Association between endometriosis and risk of histological subtypes of ovarian cancer: A pooled analysis of case-control studies. *The Lancet Oncology*, *13*(4), 385–394. [https://doi.org/10.1016/S1470-2045\(11\)70404-1](https://doi.org/10.1016/S1470-2045(11)70404-1)
- Peracchio, C., Alabiso, O., Valente, G., & Isidoro, C. (2012). Involvement of autophagy in ovarian cancer: A working hypothesis. *Journal of Ovarian Research*, *5*(1), 1–10. <https://doi.org/10.1186/1757-2215-5-22>
- Perlman, B., Kulak, D., Goldsmith, L. T., & Weiss, G. (2018). The etiology of menopause: not just ovarian dysfunction but also a role for the central nervous system. *Global Reproductive Health*, *3*(2), e8–e8. <https://doi.org/10.1097/grh.0000000000000008>
- Prat, J., D'Angelo, E., & Espinosa, I. (2018). Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics. *Human Pathology*, *80*, 11–27. <https://doi.org/10.1016/j.humpath.2018.06.018>
- Ren, Y., Jiang, R., Yin, S., You, C., Liu, D., Cheng, X., Tang, J., & Zang, R. (2015). *Radical surgery versus standard surgery for primary cytoreduction of bulky stage IIIc and IV ovarian cancer: an observational study*. 1–12. <https://doi.org/10.1186/s12885-015-1525-1>
- Rizzuto, I., Stavraka, C., Chatterjee, J., Borley, J., Hopkins, T. G., Gabra, H., Ghaem-Maghami, S., Huson, L., & Blagden, S. P. (2015). Risk of ovarian cancer relapse score: A prognostic algorithm to predict relapse following treatment for advanced ovarian cancer. *International Journal of Gynecological Cancer*, *25*(3), 416–422. <https://doi.org/10.1097/IGC.0000000000000361>
- Salveti, N. R., Baravalle, C., Mira, G. A., Gimeno, E. J., Dallard, B. E., Rey, F., & Ortega, H. H. (2009). Heat shock protein 70 and sex steroid receptors in the follicular structures of induced ovarian cysts. *Reproduction in Domestic Animals*,

44(5), 805–814. <https://doi.org/10.1111/j.1439-0531.2008.01086.x>

Shen, F., Zhang, X., Zhang, Y., Ding, J., & Chen, Q. (2017). Hormone receptors expression in ovarian cancer taking into account menopausal status: A retrospective study in Chinese population. *Oncotarget*, 8(48), 84019–84027. <https://doi.org/10.18632/oncotarget.20251>

Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021). Cancer Statistics, 2021. *CA: A Cancer Journal for Clinicians*, 71(1), 7–33. <https://doi.org/10.3322/caac.21654>

Sieh, W., Köbel, M., Longacre, T. A., Bowtell, D. D., deFazio, A., Goodman, M. T., Høgdall, E., Deen, S., Wentzensen, N., Moysich, K. B., Brenton, J. D., Clarke, B. A., Menon, U., Gilks, C. B., Kim, A., Madore, J., Fereday, S., George, J., Galletta, L., ... Ramus, S. J. (2013). Hormone-receptor expression and ovarian cancer survival: An Ovarian Tumor Tissue Analysis consortium study. *The Lancet Oncology*, 14(9), 853–862. [https://doi.org/10.1016/S1470-2045\(13\)70253-5](https://doi.org/10.1016/S1470-2045(13)70253-5)

Syam, D. M., Magister, P., Klinis, K., Obstetri, D., Ginekologi, D. A. N., Kedokteran, F., & Sumatera, U. (2018). *Analisis faktor faktor yang berhubungan dengan kejadian rekurensi kanker ovarium epitel di rsup h adam malik medan tahun 2018 tesis magister.*

Tate, S., Nishikimi, K., Matsuoka, A., & Shozu, M. (2020). Aggressive surgery for advanced ovarian cancer decreases the risk of intraperitoneal recurrence. *International Journal of Clinical Oncology*, 0123456789. <https://doi.org/10.1007/s10147-020-01714-w>

The World Ovarian Cancer Coalition. (2018). The World Ovarian Cancer Coalition Atlas: Global Trends in Incidence, Mortality and Survival. *The Every Woman Study*, April, 1–39.

- Tortorella, L., Vizzielli, G., Fusco, D., Cho, W. C., Bernabei, R., Scambia, G., & Colloca, G. (2017). Ovarian cancer management in the oldest old: Improving outcomes and tailoring treatments. *Aging and Disease*, 8(5), 677–684. <https://doi.org/10.14336/AD.2017.0607>
- Ushijima, K. (2010). Treatment for recurrent ovarian cancer - At first relapse. *Journal of Oncology*, 2010(di). <https://doi.org/10.1155/2010/497429>
- Vargas-Hernández, V. M., Moreno-Eutimio, M. A., Acosta-Altamirano, G., & Vargas-Aguilar, V. M. (2014). Management of recurrent epithelial ovarian cancer. *Gland Surgery*, 3(3), 198–202. <https://doi.org/10.3978/j.issn.2227-684X.2013.10.01>
- Vostakolaei, M. A., Hatami-Baroogh, L., Babaei, G., Molavi, O., Kordi, S., & Abdolalizadeh, J. (2021). Hsp70 in cancer: A double agent in the battle between survival and death. *Journal of Cellular Physiology*, 236(5), 3420–3444. <https://doi.org/10.1002/jcp.30132>
- Wang, X., Chen, M., Zhou, J., & Zhang, X. (2014). HSP27, 70 and 90, anti-apoptotic proteins, in clinical cancer therapy (review). *International Journal of Oncology*, 45(1), 18–30. <https://doi.org/10.3892/ijo.2014.2399>
- Where, L. S., Response, C. F. O. R., Defined, A. S., Are, B., By, R., Standard, O. T., Further, E., Trials, E., Of, V., & To, E. A. (2005). *CA 125 definitions agreed by GCIG November 2005. November*.
- Wright, J. D., Chen, L., Tergas, A. I., Patankar, S., Burke, W. M., Hou, J. Y., Neugut, A. I., Ananth, C. V., & Hershman, D. L. (2015). Trends in relative survival for ovarian cancer from 1975 to 2011. *Obstetrics and Gynecology*, 125(6), 1345–1352. <https://doi.org/10.1097/AOG.0000000000000854>
- Yang, L., Li, H., Jiang, Y., Zuo, J., & Liu, W. (2013). Inhibition of mortalin expression reverses cisplatin resistance and attenuates growth of ovarian cancer cells. *Cancer Letters*, 336(1), 213–221.

<https://doi.org/10.1016/j.canlet.2013.05.004>

Yang, X., Wang, J., Zhou, Y., Wang, Y., Wang, S., & Zhang, W. (2012). Hsp70 promotes chemoresistance by blocking Bax mitochondrial translocation in ovarian cancer cells. *Cancer Letters*, 321(2), 137–143.  
<https://doi.org/10.1016/j.canlet.2012.01.030>